ES2890226T3 - Compuestos de benzodiazolio como inhibidores del ENaC - Google Patents
Compuestos de benzodiazolio como inhibidores del ENaC Download PDFInfo
- Publication number
- ES2890226T3 ES2890226T3 ES17807900T ES17807900T ES2890226T3 ES 2890226 T3 ES2890226 T3 ES 2890226T3 ES 17807900 T ES17807900 T ES 17807900T ES 17807900 T ES17807900 T ES 17807900T ES 2890226 T3 ES2890226 T3 ES 2890226T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- ethyl
- amino
- pyrrolo
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 **(C=C1)C=Cc2c1[n](*)c(CNC(c1nc(c(*)c(*)[n]3)c3nc1N)=O)[n+]2* Chemical compound **(C=C1)C=Cc2c1[n](*)c(CNC(c1nc(c(*)c(*)[n]3)c3nc1N)=O)[n+]2* 0.000 description 19
- CRCZPRHYWDKNBB-UHFFFAOYSA-N C=C(C(F)(F)F)O Chemical compound C=C(C(F)(F)F)O CRCZPRHYWDKNBB-UHFFFAOYSA-N 0.000 description 2
- ZYQDUZXGRVKQIH-XBXGWEOASA-N CC(C)(C)OC(N(C)CCCN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)=O Chemical compound CC(C)(C)OC(N(C)CCCN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)=O ZYQDUZXGRVKQIH-XBXGWEOASA-N 0.000 description 1
- UBRZVFBAPAUSBV-UHFFFAOYSA-N CC(C)(C)OC(NCCCNC(OCC1c(cccc2)c2-c2ccccc12)=O)=O Chemical compound CC(C)(C)OC(NCCCNC(OCC1c(cccc2)c2-c2ccccc12)=O)=O UBRZVFBAPAUSBV-UHFFFAOYSA-N 0.000 description 1
- NXAKRVADEMLOPT-UHFFFAOYSA-N CC(C)(C)OC(NCCN(CC1)CCC1N)=O Chemical compound CC(C)(C)OC(NCCN(CC1)CCC1N)=O NXAKRVADEMLOPT-UHFFFAOYSA-N 0.000 description 1
- ZPPQQEDMNHNPGD-INIZCTEOSA-N CC(C)(C)OC(NCC[C@@H](C(N)=O)NCCCNC(OCc1ccccc1)=O)=O Chemical compound CC(C)(C)OC(NCC[C@@H](C(N)=O)NCCCNC(OCc1ccccc1)=O)=O ZPPQQEDMNHNPGD-INIZCTEOSA-N 0.000 description 1
- YWPCTUISODBHNP-UHFFFAOYSA-N CC(C)(C)OC(NCCc(cc1)ccc1-c1ccc(CC#N)cc1)=O Chemical compound CC(C)(C)OC(NCCc(cc1)ccc1-c1ccc(CC#N)cc1)=O YWPCTUISODBHNP-UHFFFAOYSA-N 0.000 description 1
- AOMKVPKFNNEPLP-UHFFFAOYSA-N CCC(C1)=C(CNC(c2nc(cc[nH]3)c3nc2N)=O)N(CC)c2c1ccc(Cl)c2 Chemical compound CCC(C1)=C(CNC(c2nc(cc[nH]3)c3nc2N)=O)N(CC)c2c1ccc(Cl)c2 AOMKVPKFNNEPLP-UHFFFAOYSA-N 0.000 description 1
- CXVJPMIBHJWFPN-JZXLJBGVSA-N CCCC(c(cc(cc1)OCCCN(C[C@@H]([C@H]([C@@H]2OC(c3ccccc3)OC[C@H]2O)O)O)C[C@@H]([C@H]([C@@H]2OC(c3ccccc3)OC[C@H]2O)O)O)c1N(CC)C(CN)=C)=O Chemical compound CCCC(c(cc(cc1)OCCCN(C[C@@H]([C@H]([C@@H]2OC(c3ccccc3)OC[C@H]2O)O)O)C[C@@H]([C@H]([C@@H]2OC(c3ccccc3)OC[C@H]2O)O)O)c1N(CC)C(CN)=C)=O CXVJPMIBHJWFPN-JZXLJBGVSA-N 0.000 description 1
- KTARMXVUARLDBL-UHFFFAOYSA-N CCCCc1c(CNC(c2c(N)nc3[nH]ccc3n2)=O)[n](CC)c2c1ccc(OCCN)c2 Chemical compound CCCCc1c(CNC(c2c(N)nc3[nH]ccc3n2)=O)[n](CC)c2c1ccc(OCCN)c2 KTARMXVUARLDBL-UHFFFAOYSA-N 0.000 description 1
- KJNAQLAYFMMSMJ-UHFFFAOYSA-N CCN1c(ccc(C(N(CC2)CCC2NC(OC(C)(C)C)=O)=O)c2)c2N(CC)C1CNC(C1=Nc(cc[nH]2)c2NC1(C)N)=O Chemical compound CCN1c(ccc(C(N(CC2)CCC2NC(OC(C)(C)C)=O)=O)c2)c2N(CC)C1CNC(C1=Nc(cc[nH]2)c2NC1(C)N)=O KJNAQLAYFMMSMJ-UHFFFAOYSA-N 0.000 description 1
- FXSJFDQFYUXDQP-UHFFFAOYSA-N CC[n]1c(cc(C(F)(F)F)cc2)c2p(C)c1CN Chemical compound CC[n]1c(cc(C(F)(F)F)cc2)c2p(C)c1CN FXSJFDQFYUXDQP-UHFFFAOYSA-N 0.000 description 1
- JCIQSPAVEYBSJO-UHFFFAOYSA-N CC[n]1c(cc(C(F)(F)F)cc2)c2p(C)c1CNC(OC(C)(C)C)=O Chemical compound CC[n]1c(cc(C(F)(F)F)cc2)c2p(C)c1CNC(OC(C)(C)C)=O JCIQSPAVEYBSJO-UHFFFAOYSA-N 0.000 description 1
- CASUFGHKZFMHIT-UHFFFAOYSA-N CC[n]1c(cc(CCCNC(OC(C)(C)C)=O)cc2)c2nc1CN(C(c1c2cccc1)=O)C2=O Chemical compound CC[n]1c(cc(CCCNC(OC(C)(C)C)=O)cc2)c2nc1CN(C(c1c2cccc1)=O)C2=O CASUFGHKZFMHIT-UHFFFAOYSA-N 0.000 description 1
- AAIWSCWUTBAKAF-UHFFFAOYSA-N CC[n]1c(cc(cc2)Br)c2nc1CN(C(c1c2cccc1)=O)C2=O Chemical compound CC[n]1c(cc(cc2)Br)c2nc1CN(C(c1c2cccc1)=O)C2=O AAIWSCWUTBAKAF-UHFFFAOYSA-N 0.000 description 1
- IBWHEQHMFNRQLM-UHFFFAOYSA-N CC[n]1c(cc(cc2)C(O)=O)c2nc1CN Chemical compound CC[n]1c(cc(cc2)C(O)=O)c2nc1CN IBWHEQHMFNRQLM-UHFFFAOYSA-N 0.000 description 1
- VOUBXLRKWXTZFC-UHFFFAOYSA-N CC[n]1c(cc(cc2)C(OC(C)(C)C)=O)c2nc1CNC(OCc1ccccc1)=O Chemical compound CC[n]1c(cc(cc2)C(OC(C)(C)C)=O)c2nc1CNC(OCc1ccccc1)=O VOUBXLRKWXTZFC-UHFFFAOYSA-N 0.000 description 1
- HIOHBJKERHRYKK-UHFFFAOYSA-N CC[n]1c(cc(cc2)C(OC)=O)c2nc1CNC(OC(C)(C)C)=O Chemical compound CC[n]1c(cc(cc2)C(OC)=O)c2nc1CNC(OC(C)(C)C)=O HIOHBJKERHRYKK-UHFFFAOYSA-N 0.000 description 1
- RPVPQFODRFKIPA-UHFFFAOYSA-N CC[n]1c(cc(cc2)Cl)c2nc1CN(C(c1c2cccc1)=O)C2=O Chemical compound CC[n]1c(cc(cc2)Cl)c2nc1CN(C(c1c2cccc1)=O)C2=O RPVPQFODRFKIPA-UHFFFAOYSA-N 0.000 description 1
- VJLXYMINFIWXJV-UHFFFAOYSA-N CC[n]1c(cc(cc2)OCCCNC(OC(C)(C)C)=O)c2nc1CNC(OCC1c2ccccc2-c2ccccc12)=O Chemical compound CC[n]1c(cc(cc2)OCCCNC(OC(C)(C)C)=O)c2nc1CNC(OCC1c2ccccc2-c2ccccc12)=O VJLXYMINFIWXJV-UHFFFAOYSA-N 0.000 description 1
- CDUYWLCYIYTGCX-UHFFFAOYSA-N COC(c(nc12)c(N)nc1[n](COCC[Si+](C)(C)C)cc2C#N)=O Chemical compound COC(c(nc12)c(N)nc1[n](COCC[Si+](C)(C)C)cc2C#N)=O CDUYWLCYIYTGCX-UHFFFAOYSA-N 0.000 description 1
- KKDUEQBKFRCXSH-UHFFFAOYSA-N NCC(CC1)CCN1C(OCC1c2ccccc2-c2c1cccc2)=O Chemical compound NCC(CC1)CCN1C(OCC1c2ccccc2-c2c1cccc2)=O KKDUEQBKFRCXSH-UHFFFAOYSA-N 0.000 description 1
- UMUSQTRXUQXFQA-QFPCDXEJSA-N NCCCN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O Chemical compound NCCCN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O UMUSQTRXUQXFQA-QFPCDXEJSA-N 0.000 description 1
- RNVLKSOXBSATJW-GASCZTMLSA-N N[C@H](CC1)CC[C@H]1NC(OCC1c2ccccc2-c2c1cccc2)=O Chemical compound N[C@H](CC1)CC[C@H]1NC(OCC1c2ccccc2-c2c1cccc2)=O RNVLKSOXBSATJW-GASCZTMLSA-N 0.000 description 1
- YENVPXQJWFSSRK-UHFFFAOYSA-N Nc1nc([nH]cc2)c2nc1C([n]1cncc1)=O Chemical compound Nc1nc([nH]cc2)c2nc1C([n]1cncc1)=O YENVPXQJWFSSRK-UHFFFAOYSA-N 0.000 description 1
- DHFDZHZHURSLDI-UHFFFAOYSA-N O=C(NC1CCNCC1)OCC1c2ccccc2-c2ccccc12 Chemical compound O=C(NC1CCNCC1)OCC1c2ccccc2-c2ccccc12 DHFDZHZHURSLDI-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- JJEWLCLLKVXSFI-AJEQDSBPSA-N O[C@@H](CN(CCOCCOCCOCCNC(OCC1c(cccc2)c2-c2c1cccc2)=O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)[C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O Chemical compound O[C@@H](CN(CCOCCOCCOCCNC(OCC1c(cccc2)c2-c2c1cccc2)=O)C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)[C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O JJEWLCLLKVXSFI-AJEQDSBPSA-N 0.000 description 1
- KMUSIARGJMDKPC-KFWFLNGKSA-N O[C@@H](CN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C1CCNCC1)[C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O Chemical compound O[C@@H](CN(C[C@@H]([C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O)O)C1CCNCC1)[C@H]([C@@H]1OC(c2ccccc2)OC[C@H]1O)O KMUSIARGJMDKPC-KFWFLNGKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1619694.1A GB201619694D0 (en) | 2016-11-22 | 2016-11-22 | Compounds |
| PCT/GB2017/053499 WO2018096325A1 (en) | 2016-11-22 | 2017-11-22 | Benzodiazolium compounds as enac inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2890226T3 true ES2890226T3 (es) | 2022-01-18 |
Family
ID=57993838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17807900T Active ES2890226T3 (es) | 2016-11-22 | 2017-11-22 | Compuestos de benzodiazolio como inhibidores del ENaC |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10941149B2 (https=) |
| EP (1) | EP3544981B1 (https=) |
| JP (1) | JP6980014B2 (https=) |
| KR (1) | KR102517273B1 (https=) |
| CN (1) | CN110214141B (https=) |
| AU (1) | AU2017364308B2 (https=) |
| CA (1) | CA3043132A1 (https=) |
| DK (1) | DK3544981T3 (https=) |
| EA (1) | EA039607B1 (https=) |
| ES (1) | ES2890226T3 (https=) |
| GB (1) | GB201619694D0 (https=) |
| HU (1) | HUE055692T2 (https=) |
| IL (1) | IL266745B (https=) |
| MA (1) | MA46878A (https=) |
| MX (1) | MX389496B (https=) |
| PL (1) | PL3544981T3 (https=) |
| PT (1) | PT3544981T (https=) |
| TW (1) | TWI756305B (https=) |
| WO (1) | WO2018096325A1 (https=) |
| ZA (1) | ZA201902710B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) * | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| GB201717051D0 (en) * | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| GB201801355D0 (en) | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
| GB201808093D0 (en) * | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| GB201908453D0 (en) | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
| PH12021553110A1 (en) | 2019-06-12 | 2022-08-01 | Tmem16A Ltd | Compounds for treating respiratory disease |
| GB201910608D0 (en) * | 2019-07-24 | 2019-09-04 | Enterprise Therapeutics Ltd | Compounds |
| EP4259607A1 (en) | 2020-12-11 | 2023-10-18 | Tmem16A Limited | Benzimidazole derivatives for treating respiratory disease |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| GB202406247D0 (en) | 2024-05-03 | 2024-06-19 | Enterprise Therapeutics Ltd | Compounds and pharmaceutical compositions |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858614B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenolic guanidine sodium channel blockers |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US6903105B2 (en) | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| US20050090505A1 (en) | 2003-08-18 | 2005-04-28 | Johnson Michael R. | Methods of reducing risk of infection from pathogens |
| US7375107B2 (en) | 2003-08-18 | 2008-05-20 | Parion Sciences, Inc. | Alaphatic pyrazinoylguanidine sodium channel blockers |
| JP2007502829A (ja) | 2003-08-18 | 2007-02-15 | パリオン・サイエンシィズ・インコーポレーテッド | 環状ピラジノイルグアニジンナトリウムチャネルブロッカー |
| ES2432529T3 (es) | 2003-08-18 | 2013-12-04 | Parion Sciences, Inc. | Bloqueadores del canal de sodio de pirazinoilguanidina rematada |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| EP1678145A2 (en) * | 2003-10-28 | 2006-07-12 | Vertex Pharmaceuticals Incorporated | Benzimidazoles useful as modulators of ion channels |
| US7399766B2 (en) | 2004-08-18 | 2008-07-15 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| ES2400287T3 (es) * | 2005-03-14 | 2013-04-08 | High Point Pharmaceuticals, Llc | Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa |
| US7807834B2 (en) | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| GB0526240D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| US8288391B2 (en) | 2007-04-03 | 2012-10-16 | Parion Sciences, Inc. | Pyrazinoylguanidine compounds for use as taste modulators |
| DE602008005140D1 (de) | 2007-05-07 | 2011-04-07 | Novartis Ag | Organische verbindungen |
| WO2009019506A1 (en) | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | Heterocyclyc sulfonamides having edg-1 antagonistic activity |
| MX2010006421A (es) | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
| ES2485642T3 (es) | 2008-02-26 | 2014-08-14 | Parion Sciences, Inc. | Bloqueantes poli-aromáticos de los canales de sodio |
| CA2723938A1 (en) | 2008-05-13 | 2009-11-19 | Novartis Ag | 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases |
| JP2011522860A (ja) | 2008-06-10 | 2011-08-04 | ノバルティス アーゲー | 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体 |
| WO2011028740A1 (en) | 2009-09-03 | 2011-03-10 | Glaxo Group Limited | ENaC BLOCKERS |
| WO2011079087A1 (en) | 2009-12-23 | 2011-06-30 | Glaxo Group Limited | Enac blockers |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| TW201204353A (en) * | 2010-06-08 | 2012-02-01 | Vertex Pharma | Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| KR102006612B1 (ko) | 2011-11-02 | 2019-08-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 헤테로사이클릭 화합물, 상기 화합물을 포함하는 약제, 이의 용도, 및 이의 제조 방법 |
| US8859559B2 (en) | 2011-12-20 | 2014-10-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazines and their use in the treatment of disease |
| HUE039734T2 (hu) | 2012-05-29 | 2019-01-28 | Parion Sciences Inc | Nátriumcsatorna-blokkoló aktivitású, dendrimerszerû amino-amid-származékok száraz szem és más nyálkahártya-megbetegedések kezelésére |
| US8841309B2 (en) | 2012-09-24 | 2014-09-23 | Boehringer Ingelheim International Gmbh | Substituted pyrazines and their use in the treatment of disease |
| ES2674665T3 (es) | 2012-12-17 | 2018-07-03 | Parion Sciences, Inc. | Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida |
| CA2895512C (en) | 2012-12-17 | 2021-10-19 | Parion Sciences, Inc. | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
| CN108658876A (zh) | 2012-12-17 | 2018-10-16 | 帕里昂科学公司 | 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物 |
| EP2991981B1 (en) | 2013-04-30 | 2017-03-01 | Boehringer Ingelheim International GmbH | Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof |
| AU2014284268A1 (en) | 2013-07-02 | 2016-01-07 | The California Institute For Biomedical Research | Compounds for treatment of cystic fibrosis |
| EP3019492B1 (en) | 2013-07-08 | 2017-09-06 | Boehringer Ingelheim International GmbH | Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways |
| EP3022197B1 (en) | 2013-07-15 | 2017-09-06 | Boehringer Ingelheim International GmbH | Novel tetra- and pentasubstituted benzimidazolium compounds |
| JP6461134B2 (ja) | 2013-07-15 | 2019-01-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ベンゾイミダゾリウム化合物 |
| WO2015007516A1 (en) | 2013-07-15 | 2015-01-22 | Boehringer Ingelheim International Gmbh | Novel 5-substituted benzimidazolium compounds |
| WO2015018754A1 (en) | 2013-08-08 | 2015-02-12 | Boehringer Ingelheim International Gmbh | Novel pyrazine amide compounds |
| WO2016113169A1 (en) | 2015-01-12 | 2016-07-21 | Boehringer Ingelheim International Gmbh | Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| EP3245199B1 (en) * | 2015-01-12 | 2020-01-01 | Boehringer Ingelheim International GmbH | Substituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| JP6847838B2 (ja) | 2015-01-12 | 2021-03-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 上皮ナトリウムチャネル阻害剤としての２−（ピラジン−２−イルカルボニルアミノメチル）ベンズイミダゾリウム化合物 |
| US9932324B2 (en) | 2015-01-12 | 2018-04-03 | Boehringer Ingelheim International Gmbh | Substituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| MX370598B (es) | 2015-08-20 | 2019-12-18 | Boehringer Ingelheim Int | Fenoxiacetamidas apareadas novedosas. |
| EA201890532A1 (ru) | 2015-08-20 | 2018-09-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые аннелированные бензамиды |
| GB201610854D0 (en) * | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) * | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
-
2016
- 2016-11-22 GB GBGB1619694.1A patent/GB201619694D0/en not_active Ceased
-
2017
- 2017-11-22 US US16/462,794 patent/US10941149B2/en active Active
- 2017-11-22 CA CA3043132A patent/CA3043132A1/en active Pending
- 2017-11-22 WO PCT/GB2017/053499 patent/WO2018096325A1/en not_active Ceased
- 2017-11-22 PT PT178079000T patent/PT3544981T/pt unknown
- 2017-11-22 MA MA046878A patent/MA46878A/fr unknown
- 2017-11-22 HU HUE17807900A patent/HUE055692T2/hu unknown
- 2017-11-22 TW TW106140573A patent/TWI756305B/zh active
- 2017-11-22 MX MX2019005934A patent/MX389496B/es unknown
- 2017-11-22 JP JP2019527365A patent/JP6980014B2/ja active Active
- 2017-11-22 AU AU2017364308A patent/AU2017364308B2/en active Active
- 2017-11-22 EA EA201991253A patent/EA039607B1/ru unknown
- 2017-11-22 CN CN201780084165.3A patent/CN110214141B/zh active Active
- 2017-11-22 ES ES17807900T patent/ES2890226T3/es active Active
- 2017-11-22 PL PL17807900T patent/PL3544981T3/pl unknown
- 2017-11-22 DK DK17807900.0T patent/DK3544981T3/da active
- 2017-11-22 KR KR1020197016141A patent/KR102517273B1/ko active Active
- 2017-11-22 EP EP17807900.0A patent/EP3544981B1/en active Active
-
2019
- 2019-04-30 ZA ZA2019/02710A patent/ZA201902710B/en unknown
- 2019-05-20 IL IL266745A patent/IL266745B/en unknown
-
2020
- 2020-11-24 US US17/103,559 patent/US11739094B2/en active Active
-
2023
- 2023-06-30 US US18/345,840 patent/US12371436B2/en active Active
-
2025
- 2025-06-11 US US19/235,076 patent/US20250304590A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2890226T3 (es) | Compuestos de benzodiazolio como inhibidores del ENaC | |
| EP3794002B1 (en) | Compounds | |
| CN103649089B (zh) | 作为pi3k抑制剂的吡咯并三嗪酮 | |
| EP3472154B1 (en) | Compounds | |
| MX2015004327A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k. | |
| TW201446767A (zh) | 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物 | |
| EP3697788B1 (en) | Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1h-1,3-benzodiazol-3-ium derivatives as enac inhibitors for treating respiratory diseases | |
| BR112019009864B1 (pt) | Compostos de benzodiazolínio, composição farmacêutica e produto compreendendo os referidos compostos, seus processos de fabricação e uso | |
| HK40014276B (en) | Benzodiazolium compounds as enac inhibitors | |
| HK40014276A (en) | Benzodiazolium compounds as enac inhibitors |